213 related articles for article (PubMed ID: 18060472)
1. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients.
Capo CR; Arciello M; Squitti R; Cassetta E; Rossini PM; Calabrese L; Rossi L
Biometals; 2008 Jun; 21(3):367-72. PubMed ID: 18060472
[TBL] [Abstract][Full Text] [Related]
2. Excess of serum copper not related to ceruloplasmin in Alzheimer disease.
Squitti R; Pasqualetti P; Dal Forno G; Moffa F; Cassetta E; Lupoi D; Vernieri F; Rossi L; Baldassini M; Rossini PM
Neurology; 2005 Mar; 64(6):1040-6. PubMed ID: 15781823
[TBL] [Abstract][Full Text] [Related]
3. Ceruloplasmin in neurodegenerative diseases.
Vassiliev V; Harris ZL; Zatta P
Brain Res Brain Res Rev; 2005 Nov; 49(3):633-40. PubMed ID: 16269323
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease.
Squitti R; Simonelli I; Ventriglia M; Siotto M; Pasqualetti P; Rembach A; Doecke J; Bush AI
J Alzheimers Dis; 2014; 38(4):809-22. PubMed ID: 24072069
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives.
Arnal N; Cristalli DO; de Alaniz MJ; Marra CA
Brain Res; 2010 Mar; 1319():118-30. PubMed ID: 20026314
[TBL] [Abstract][Full Text] [Related]
6. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
Boström F; Hansson O; Gerhardsson L; Lundh T; Minthon L; Stomrud E; Zetterberg H; Londos E
Neurobiol Aging; 2009 Aug; 30(8):1265-71. PubMed ID: 18191875
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum copper and ceruloplasmin levels in Alzheimer's disease.
Park JH; Lee DW; Park KS
Asia Pac Psychiatry; 2014 Mar; 6(1):38-45. PubMed ID: 23857910
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
10. Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study.
Squitti R; Simonelli I; Cassetta E; Lupoi D; Rongioletti M; Ventriglia M; Siotto M
Curr Alzheimer Res; 2017; 14(12):1318-1326. PubMed ID: 28669331
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease.
Rembach A; Doecke JD; Roberts BR; Watt AD; Faux NG; Volitakis I; Pertile KK; Rumble RL; Trounson BO; Fowler CJ; Wilson W; Ellis KA; Martins RN; Rowe CC; Villemagne VL; Ames D; Masters CL; AIBL research group ; Bush AI
J Alzheimers Dis; 2013; 34(1):171-82. PubMed ID: 23168449
[TBL] [Abstract][Full Text] [Related]
12. Copper and ceruloplasmin dyshomeostasis in serum and cerebrospinal fluid of multiple sclerosis subjects.
De Riccardis L; Buccolieri A; Muci M; Pitotti E; De Robertis F; Trianni G; Manno D; Maffia M
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1828-1838. PubMed ID: 29524632
[TBL] [Abstract][Full Text] [Related]
13. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease.
Loeffler DA; DeMaggio AJ; Juneau PL; Brickman CM; Mashour GA; Finkelman JH; Pomara N; LeWitt PA
Alzheimer Dis Assoc Disord; 1994; 8(3):190-7. PubMed ID: 7986488
[TBL] [Abstract][Full Text] [Related]
14. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
[TBL] [Abstract][Full Text] [Related]
15. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
Yin GN; Lee HW; Cho JY; Suk K
Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
[TBL] [Abstract][Full Text] [Related]
16. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
Isobe C; Murata T; Sato C; Terayama Y
Life Sci; 2005 Aug; 77(15):1836-43. PubMed ID: 15935398
[TBL] [Abstract][Full Text] [Related]
17. Ceruloplasmin in neurodegenerative diseases.
Texel SJ; Xu X; Harris ZL
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1277-81. PubMed ID: 19021540
[TBL] [Abstract][Full Text] [Related]
18. Alteration of peripheral markers of copper homeostasis in Alzheimer's disease patients: implications in aetiology and therapy.
Rossi L; Squitti R; Calabrese L; Rotilio G; Rossini PM
J Nutr Health Aging; 2007; 11(5):408-17. PubMed ID: 17657362
[TBL] [Abstract][Full Text] [Related]
19. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Lundh T; Minthon L; Londos E
Dement Geriatr Cogn Disord; 2008; 25(6):508-15. PubMed ID: 18463412
[TBL] [Abstract][Full Text] [Related]
20. Ceruloplasmin, an indicator of copper status.
Arredondo M; González M; Olivares M; Pizarro F; Araya M
Biol Trace Elem Res; 2008; 123(1-3):261-9. PubMed ID: 18270661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
